Healthcare
Rapid Dose Therapeutics Corp.(RDTCF)
Live Price
Offline$0.0132
+0.00% today
1Y Change
-53.27%
Window
Jun 23, 2025 โ Jun 10, 2026
- Market Cap
- $10.00M
- Revenue Growth
- +104.4%
- EPS Growth
- +2.4%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rapid Dose Therapeutics Corp. (RDTCF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.01 and down 53.3% across the available one-year price window (Jun 23, 2025 โ Jun 10, 2026). Baseline metrics include revenue growth of +104.4%, EPS growth of +2.4%, a dividend yield of 0.0%. What stands out right now is revenue +104.4%, EPS +2.4%, free cash flow +49.8% with operating margin -110.7% and ROIC 543.8%. Valuation sits in the middle of the pack at price/sales 4.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RDTCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+104.4% vs +7.6% peer median
Operating Margin
Below sector median
-110.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jan 27, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +104.4% and EPS at +2.4%, with operating margin around -110.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.2% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jan 27, 2026 | โ | +0.0% | -15.6% | +22.2% |
2025 Oct 28, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 Jun 30, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RDTCF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
RDTCF Max Drawdown
-56.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for RDTCF and SPY.
Company Overview
Rapid Dose Therapeutics Corp.
Other OTC
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies designed to enhance outcomes and quality of lives in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release active ingredients into the blood stream, such as pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in the system; and QuickStrip sleep that delivers melatonin in the system. The company also provides product innovation, production, and consultation services to the nutraceutical, cannabis healthcare, and pharmaceutical manufacturing industries. It has a research partnership program with McMaster University for developing biopolymer compositions that can offer enhanced drug delivery performance when formulated in oral dissolvable thin films, as well as for developing orally delivered vaccine candidate for COVID-19. Rapid Dose Therapeutics Corp. is based in Burlington, Canada.
- Leadership
- Mark Andrew Upsdell
- IPO Date
- Sep 27, 2019
- Employees
- 12
- Street Address
- 1121 Walkers Line
- Mailing
- Burlington, ON, L7N 2G4
- Region
- Burlington, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 416 477 1052
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.7
- Price/Book
- โ
Growth
- Revenue
- +104.4%
- EPS
- +2.4%
- Free Cash Flow
- +49.8%
Profitability
- Gross Margin
- 29.8%
- Operating Margin
- -110.7%
- Net Margin
- -157.2%
- ROE
- 75.8%
- ROIC
- 543.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.08
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.